| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $300,000 ) |
| | 2025 | 2025 | ORLANCE, INC | 401 TERRY AVE N | SEATTLE | WA | 98109-5263 | KING | USA | R43AI181303 | Gene Gun-delivered RNA vaccines. | 001 | 2 | NIH | 4/17/2025 | $300,000 |
| | 2025 | 2024 | ORLANCE, INC | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R44AI179440 | Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine | 000 | 2 | NIH | 11/22/2024 | $0 |
| | 2025 | 2024 | ORLANCE, INC | 401 TERRY AVE N | SEATTLE | WA | 98109-5263 | KING | USA | R43CA281585 | Next Generation Gene-Gun Delivered DNA and RNA Immunotherapeutic Vaccines for Melanoma. | 000 | 2 | NIH | 4/4/2025 | $0 |
| | 2025 | 2024 | ORLANCE, INC | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R43AI181303 | Gene Gun-delivered RNA vaccines. | 000 | 1 | NIH | 11/26/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $2,790,275 ) |
| | 2024 | 2024 | ORLANCE, INC | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R43AI181303 | Gene Gun-delivered RNA vaccines. | 001 | 1 | NIH | 6/26/2024 | $0 |
| | 2024 | 2024 | ORLANCE, INC | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R43CA281585 | Next Generation Gene-Gun Delivered DNA and RNA Immunotherapeutic Vaccines for Melanoma. | 002 | 2 | NIH | 8/1/2024 | $200,000 |
| | 2024 | 2024 | ORLANCE, INC | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R44AI153011 | Universal Influenza A/B Vaccine | 001 | 4 | NIH | 4/30/2024 | $1,000,000 |
| | 2024 | 2024 | ORLANCE, INC | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R44AI186932 | Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens | 000 | 1 | NIH | 8/8/2024 | $300,000 |
| | 2024 | 2024 | ORLANCE, INC | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R43AI181303 | Gene Gun-delivered RNA vaccines. | 000 | 1 | NIH | 5/3/2024 | $300,000 |
| | 2024 | 2024 | ORLANCE, INC | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R44AI179440 | Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine | 001 | 2 | NIH | 8/13/2024 | $990,275 |
| | 2024 | 2023 | ORLANCE, INC | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R43CA281585 | Next Generation Gene-Gun Delivered DNA and RNA Immunotherapeutic Vaccines for Melanoma. | 001 | 1 | NIH | 5/24/2024 | $0 |
| | 2024 | 2023 | ORLANCE INC | 1124 COLUMBIA ST | SEATTLE | WA | 98104-2008 | KING | USA | R43CA281585 | Next Generation Gene-Gun Delivered DNA and RNA Immunotherapeutic Vaccines for Melanoma. | 000 | 1 | NIH | 12/11/2023 | $0 |
| | 2024 | 2023 | ORLANCE, INC | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R44AI179440 | Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine | 000 | 1 | NIH | 6/24/2024 | $0 |
| | 2024 | 2021 | ORLANCE, INC | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R44AI122371 | Development of a rapid response nucleic acid vaccine strategy for coronavirus epidemics | 001 | 5 | NIH | 1/24/2024 | $0 |
| | 2024 | 2021 | ORLANCE, INC | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R44AI122371 | Development of a rapid response nucleic acid vaccine strategy for coronavirus epidemics | 000 | 5 | NIH | 1/24/2024 | $0 |
| | 2024 | 2020 | ORLANCE, INC | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R44AI153011 | Universal Influenza A/B Vaccine | 000 | 1 | NIH | 4/4/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $2,195,389 ) |
| | 2023 | 2023 | ORLANCE INC | 1124 COLUMBIA ST | SEATTLE | WA | 98104-2008 | KING | USA | R44AI153011 | Universal Influenza A/B Vaccine | 000 | 3 | NIH | 5/23/2023 | $998,889 |
| | 2023 | 2023 | ORLANCE INC | 1124 COLUMBIA ST | SEATTLE | WA | 98104-2008 | KING | USA | R43CA281585 | Next Generation Gene-Gun Delivered DNA and RNA Immunotherapeutic Vaccines for Melanoma. | 000 | 1 | NIH | 9/21/2023 | $200,000 |
| | 2023 | 2023 | ORLANCE INC | 1124 COLUMBIA ST | SEATTLE | WA | 98104-2008 | KING | USA | R44AI179440 | Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine | 000 | 1 | NIH | 8/21/2023 | $996,500 |
|
| Issue Date FY: 2022 ( Subtotal = $1,000,000 ) |
| | 2022 | 2022 | ORLANCE, INC. | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R44AI153011 | Universal Influenza A/B Vaccine | 001 | 2 | NIH | 5/3/2022 | $1,000,000 |
| | 2022 | 2021 | ORLANCE, INC. | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R44AI122371 | Development of a rapid response nucleic acid vaccine strategy for coronavirus epidemics | 000 | 5 | NIH | 9/2/2022 | $0 |
| | 2022 | 2020 | ORLANCE, INC. | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R44AI153011 | Universal Influenza A/B Vaccine | 000 | 1 | NIH | 4/25/2022 | $0 |
| | 2022 | 2019 | ORLANCE, INC. | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R44AI114331 | Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine | 000 | 3 | NIH | 4/14/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,955,395 ) |
| | 2021 | 2021 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R44AI122371 | Development of a rapid response nucleic acid vaccine strategy for coronavirus epidemics | 000 | 5 | NIH | 4/30/2021 | $1,000,000 |
| | 2021 | 2021 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R44AI122371 | Development of a rapid response nucleic acid vaccine strategy for coronavirus epidemics | 001 | 5 | NIH | 5/6/2021 | $955,395 |
| | 2021 | 2019 | ORLANCE, INC. | 1124 COLUMBIA ST STE 300 | SEATTLE | WA | 98104-2008 | KING | USA | R43AI140784 | Design and Optimization of Clinical Gene Gun for Delivery of Nucleic Acid Vaccines | 000 | 2 | NIH | 9/20/2021 | $0 |
| | 2021 | 2019 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R44AI114331 | Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine | 000 | 3 | NIH | 8/9/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,418,026 ) |
| | 2020 | 2020 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R44AI122371 | Development of a rapid response nucleic acid vaccine strategy for coronavirus epidemics | 002 | 4 | NIH | 8/21/2020 | -$1,000,000 |
| | 2020 | 2020 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R44AI153011 | Universal Influenza A/B Vaccine | 001 | 1 | NIH | 8/24/2020 | -$300,000 |
| | 2020 | 2020 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R44AI122371 | Development of a rapid response nucleic acid vaccine strategy for coronavirus epidemics | 000 | 4 | NIH | 4/9/2020 | $1,000,000 |
| | 2020 | 2020 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R44AI122371 | Development of a rapid response nucleic acid vaccine strategy for coronavirus epidemics | 001 | 4 | NIH | 6/2/2020 | $908,934 |
| | 2020 | 2020 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R44AI122371 | Development of a rapid response nucleic acid vaccine strategy for coronavirus epidemics | 002 | 4 | NIH | 8/21/2020 | $1,000,000 |
| | 2020 | 2020 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R44AI153011 | Universal Influenza A/B Vaccine | 000 | 1 | NIH | 8/7/2020 | $300,000 |
| | 2020 | 2020 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R44AI153011 | Universal Influenza A/B Vaccine | 001 | 1 | NIH | 8/24/2020 | $300,000 |
| | 2020 | 2019 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R44AI114331 | Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine | 001 | 3 | NIH | 12/19/2019 | $209,092 |
| | 2020 | 2019 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R43AI140784 | Design and Optimization of Clinical Gene Gun for Delivery of Nucleic Acid Vaccines | 000 | 2 | NIH | 6/5/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,868,118 ) |
| | 2019 | 2019 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R44AI122371 | Development of a rapid response nucleic acid vaccine strategy for coronavirus epidemics | 002 | 3 | NIH | 8/16/2019 | $1,000,000 |
| | 2019 | 2019 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R43AI140784 | Design and Optimization of Clinical Gene Gun for Delivery of Nucleic Acid Vaccines | 000 | 2 | NIH | 3/4/2019 | $298,613 |
| | 2019 | 2019 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R44AI114331 | Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine | 001 | 3 | NIH | 8/23/2019 | $569,505 |
| | 2019 | 2019 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R43AI140784 | Design and Optimization of Clinical Gene Gun for Delivery of Nucleic Acid Vaccines | 001 | 2 | NIH | 8/29/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $300,000 ) |
| | 2018 | 2018 | ORLANCE, INC. | 4000 15TH AVE NE | SEATTLE | WA | 98195-0008 | KING | USA | R43AI140784 | Design and Optimization of Clinical Gene Gun for Delivery of Nucleic Acid Vaccines | 000 | 1 | NIH | 4/10/2018 | $300,000 |
|
|
